Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant Mouse Antibody Fab Fragment is against Human KIR3DL1, expressed in E. coli
Recombinant full length Human KIR3DL1.
Suitable for use in FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods.
Tested positive against native antigen.
>95.0% as determined by analysis by RP-HPLC.
4°C. For long term storage, aliquot and store at -20°C. Repeated thawing and freezing must be avoided.
KIR3DL1 (NKB1, CD158e1) is expressed on a subset of natural killer cells and T cells. NKB1 is a 70 kD member of the immunoglobulin superfamily that is expressed at varying levels among individuals. NKB1 is a type I membrane protein containing two immunoglobulin C2 type domains. The interaction of NKB1 with specific HLA B antigens on a target cell (the HLA Bw4 allele, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.
HLA-B specific inhibitory MHC class I receptor activity; receptor activity;